Nov 5 (Reuters) - Contract drug manufacturer Catalent (CTLT.N), opens new tab, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below ...

Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to an open letter to customers. In the letter addressing customers ...

SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today issued the ...

Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s ...

SOMERSET, N.J. (AP) — SOMERSET, N.J. (AP) — Catalent Inc. (CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a ...

(RTTNews) - Catalent, Inc. (CTLT) said, following the closing of transaction, as a private company under Novo Holdings' ownership, Catalent will continue to operate as a global, independent ...

While the deal would not weigh heavily on Roche’s own production operations, “it could be a problem for other smaller players if there is a restriction in terms of how many CMOs are available ...

(RTTNews) - Catalent Inc. (CTLT) announced Loss for first quarter that decreased from last year The company's bottom line totaled -$129 million, or -$0.71 per share. This compares with -$759 ...

Catalent (CTLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.11. This compares to loss of $0.10 per share a year ago. These figures are adjusted for ...

Update 12:30pm: Adds Catalent response. The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Holdings to purchase Catalent ...